Kovitz Investment Group Partners LLC Has $3.03 Million Stake in Insulet Corporation $PODD

Kovitz Investment Group Partners LLC lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 27.4% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 10,672 shares of the medical instruments supplier’s stock after selling 4,031 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Insulet were worth $3,034,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in PODD. State Street Corp lifted its position in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares during the period. Geode Capital Management LLC lifted its position in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the period. Invesco Ltd. boosted its stake in Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after buying an additional 141,167 shares in the last quarter. Norges Bank bought a new stake in Insulet in the 4th quarter valued at $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Insulet by 3.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after buying an additional 29,690 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PODD. Wall Street Zen upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Bank of America lowered their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Citigroup cut their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. UBS Group set a $219.00 price objective on Insulet in a research note on Thursday, June 11th. Finally, Leerink Partners dropped their target price on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is owned by company insiders.

Insulet Price Performance

Shares of NASDAQ PODD opened at $145.76 on Friday. The firm’s 50-day simple moving average is $164.18 and its 200 day simple moving average is $226.26. The company has a market cap of $10.10 billion, a price-to-earnings ratio of 33.90, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the company posted $1.02 EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.